Last edition
News about "Phase III clinical trials"
Roche Reports Strong Phase III Results for Fenebrutinib in Multiple Sclerosis
Roche’s investigational drug fenebrutinib shows significant reduction in relapse rates and disease activity in multiple sclerosis, offering potential for improved long-term outcomes in patients.
Phase III Clinical Trials | 23/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members